NASDAQ: TECXTectonic Therapeutic Inc Stock
$27.21-0.70 (-2.51%)
Updated Sep 17, 2026
TECX Price
$27.21
Fair Value Price
$13.78
Market Cap
$531.94M
52 Week Low
$14.39
52 Week High
$39.53
P/E
-5.95x
P/B
2.38x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$85.79M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.06
Operating Cash Flow
-$72M
Beta
1.23
Next Earnings
Nov 5, 2026
Ex-Dividend
N/A
Next Dividend
N/A
TECX Overview
Tectonic Therapeutic, Inc. operates as a clinical-stage biotechnology firm dedicated to the identification and progression of biologic therapies, primarily therapeutic proteins and antibodies, that regulate the function of G-protein coupled receptors (GPCRs). The company leverages its proprietary GEODe technology platform to facilitate the discovery and development of these GPCR-targeted medicines. Its robust pipeline includes an RXFP1 agonist, currently undergoing Phase 1a and 1b clinical trials for the treatment of heart failure with preserved ejection fraction. Additional programs encompass a GPCR antagonist addressing hereditary hemorrhagic telangiectasia, a bi-functional GPCR modulator aimed at fibrosis, and various other GPCR modulators. Tectonic Therapeutic, Inc. is situated in Watertown, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine TECX's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -12.86% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
TECX
Ranked#420 of 462
Ranked#420 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.52 | A | |
| $353.46 | A | |
| $114.86 | A |
Be the first to know about important TECX news, forecast changes, insider trades & much more!
TECX News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how TECX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TECX ($27.21) is overvalued by 97.43% relative to our estimate of its Fair Value price of $13.78 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
TECX ($27.21) is not significantly undervalued (97.43%) relative to our estimate of its Fair Value price of $13.78 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
TECX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more TECX due diligence checks available for Premium users.
Valuation
TECX fair value
Fair Value of TECX stock based on Discounted Cash Flow (DCF)
Price
$27.21
Fair Value
$13.78
Overvalued by
97.43%
TECX ($27.21) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
TECX ($27.21) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
TECX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
TECX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-5.95x
Industry
9.65x
Market
45.05x
TECX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.38x
Industry
5.34x
TECX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TECX's financial health
Profit margin
Revenue
$0.0
Net Income
-$22.3M
Profit Margin
0%
TECX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$237.0M
Liabilities
$13.2M
Debt to equity
0.06
TECX's short-term assets ($231.10M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TECX's short-term assets ($231.10M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TECX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
TECX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$21.5M
Investing
-$59.0k
Financing
$11.7M
TECX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TECX vs Biotech Stocks
Tectonic Therapeutic Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.